Axsome Therapeutics (AXSM): Can the Stock Reach the $275 Analyst Target?

Key Takeaways

• The central stock price target of $275 is the arithmetic mean of the verified analyst price targets reviewed, rounded to a clean level; the underlying range spans roughly $238 to $380.
• With the latest price near $144, reaching $275 would require an upside of roughly 90% — a very large move.
• The wide $238-to-$380 target range reflects genuine disagreement about how quickly Axsome's commercial franchise and late-stage pipeline will translate into sustained profitability.
• The strongest supports are rapid revenue growth from Auvelity, a recent label expansion in Alzheimer's disease agitation, and multiple late-stage pipeline catalysts.
• The biggest risks are continued net losses, the commercial ramp of newer products, clinical and regulatory setbacks, and the recent wave of analyst target reductions.
• You can find more information about the company's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
• For AI-driven trading ideas across the market, explore Trending AI Robots.

Analyst Consensus and Recent Target Adjustments

Axsome Therapeutics carries broad but not unanimous bullish coverage. Across the verified targets reviewed, the arithmetic mean comes to roughly $275, with the low-to-high span extending from approximately $238 to $380 — an unusually wide range that underscores how differently analysts model the company's path to profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Recent revisions have skewed lower even as ratings remain positive. Mizuho trimmed its target to $284 (from $316), Piper Sandler to $238 (from $258), UBS to $256 (from $280), Deutsche Bank to $267 (from $280), and Morgan Stanley to $247, while RBC Capital, H.C. Wainwright, TD Cowen, and Truist maintained targets in the $285-to-$300 zone. These cuts followed a period of elevated expectations, reflecting more conservative near-term assumptions rather than a collapse in conviction — most firms still rate the shares Buy or Overweight.

The divergence is largely a question of valuation. Bullish analysts emphasize the growing Auvelity franchise and pipeline optionality, while more cautious voices, including Morgan Stanley's Equal Weight rating, argue that the current enterprise value already discounts meaningful execution and that profitability remains some distance away.

Current Valuation and Required Upside

Axsome's stock closed near $144 in late October 2026, down roughly 31% over the prior three months and well below its 52-week range of approximately $123.50 to $260.19. Reaching the $275 central target would require a gain of about 90%, which must be characterized as a very large move rather than an incremental recovery.

The path would almost certainly be driven by fundamentals rather than sentiment alone. Axsome is not yet profitable on a GAAP basis, so the investment case rests on accelerating revenue and eventual operating leverage. In the third quarter, total revenue reached $259.7 million, up 52% year over year, led by Auvelity net product sales of $207.6 million (up 53%). Sunosi contributed $48.2 million and newly launched Symbravo $3.9 million. Management has pointed to a commercial portfolio running above a $1 billion annualized revenue pace.

Growth Drivers That Could Support Higher Prices

• Auvelity growth and label expansion: Auvelity's recent approval in Alzheimer's disease (AD) agitation meaningfully expands its addressable market beyond major depressive disorder and is driving accelerating sequential growth.
• Late-stage pipeline catalysts: Phase 3 programs include AXS-14 in fibromyalgia and AXS-20 in schizophrenia, alongside solriamfetol for binge eating disorder, while AXS-12 in narcolepsy is under regulatory review.
• Improving revenue mix: Gross-to-net discounts have improved into the mid-to-high 40% range for Auvelity, supporting stronger net revenue realization.
• Broad Street support: Most covering analysts maintain Buy or Outperform ratings, indicating durable conviction in the long-term CNS franchise.

Key Risks to Watch

• Persistent losses: The company remains unprofitable, with elevated selling, general, and administrative costs tied to the commercial ramp of Auvelity and Symbravo.
• Clinical and regulatory risk: A setback in schizophrenia, fibromyalgia, or binge eating disorder programs, or a delay in AXS-12, could compress the valuation multiple and trigger further target cuts.
• New-product execution: Symbravo's ramp is still early, and competition in migraine and depression markets remains intense.
• Downward revision momentum: The recent series of analyst target reductions suggests the Street is tempering expectations, which can weigh on sentiment even when ratings stay positive.

Technical Picture

From a technical standpoint, Axsome is trading in the lower portion of its long-term range. The 52-week low near $123.50 represents a key support level to watch, while the $200 area is a psychological and prior-consolidation resistance level on the way toward higher objectives. The stock's decline from roughly $260 to the $144 area leaves significant overhead supply, meaning any sustained advance toward $275 would likely need to be confirmed by improving fundamentals and a durable break back above the $200 zone.

Monitoring the Path Forward

Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms differ. Investors should watch quarterly Auvelity and Sunosi trends, the Symbravo launch trajectory, regulatory decisions on AXS-12, and Phase 3 data readouts across the pipeline. Updates to analyst price targets, gross-to-net discount trends, and progress toward profitability will also be key signals for whether the gap to the $275 target narrows or widens.

Incorporating AI Signals into My Research

I have found Tickeron's AI Daily Buy/Sell Signals helpful for keeping an eye on names like Axsome that can move on catalysts or sentiment shifts. The tool monitors thousands of stocks and ETFs to generate Buy, Sell, or Hold signals based on technical behavior and AI analysis. It serves as a practical complement when I want data-driven timing alongside fundamental work.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume